Moderna is still in a Covid hangover
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Good morning and happy Friday. We discuss a new innovative immunotherapy, and we take a look at some of the earnings highlights yesterday.
Read Original Article: Moderna is still in a Covid hangover »
